Ctrl

K

Alectinib

Class
Targeted therapy
Subclass
ALK inhibitors
Generic name
Alectinib hydrochloride
Brand names
Alecensa®
Common formulations
Capsule
Dosage and administration
Adults patients
Treatment of non-small cell lung cancer in patients with ALK rearrangement • Metastatic
•
600 mg PO BID
Indications for use
Labeled indications
Adults
•
Treatment of non-small cell lung cancer in patients with ALK rearrangement (metastatic)
Pregnancy and breastfeeding
Breastfeeding
Little information available on breastfeeding safety.
Unknown amount excreted in breastmilk.
Unknown drug levels in breastfed infants.
Adverse reactions
Very common > 10%
•
AKI, anemia, bradycardia, ↓ blood lymphocyte count, edema, ↑ blood glucose, ↑ serum ALT, ↑ serum AST, ↑ serum CK, ↑ serum TBIL, abdominal pain, back pain, change in taste, constipation, cough, diarrhea, dyspnea, fatigue, headache, myalgia, nausea, skin rash, vomiting, weight gain, viral infections
Common 1-10%
•
Drug-induced liver injury, hemolytic anemia, interstitial lung disease, pulmonary embolism, photosensitivity of skin, pneumonia, pneumonitis, visual disturbances, stomatitis
Uncommon < 1%
•
Acute hemorrhage, endocarditis, gastrointestinal perforation
Unknown frequency
•
Acute appendicitis, acute pancreatitis, cardiac arrest, ↑ serum triglycerides, myocardial infarction, sudden death syndrome
Interactions
Drug(s)
Check Interactions
Reset

What did you think about this content?

Create free account

Sign up for free to access the full drug resource